Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
Director Dawn Halkuff sold 42,500 shares of Xeris Biopharma Holdings, Inc. NASDAQ:XERS on August 12, 2025. The transaction comes as the stock trades near its 52-week high of $7.61, having surged over 100% in the past six months. The shares were sold at a weighted average price of $7.2759, resulting in a total transaction value of $309,225.
The sales were executed in multiple transactions with prices ranging from $7.190 to $7.450. Following the transaction, Halkuff directly owns 115,000 shares of Xeris Biopharma.
Halkuff also indirectly owns 5,410 shares through the DAWN HALKUFF REVOCABLE TRUST U/A DTD 08/25/2017.
In other recent news, Xeris Pharmaceuticals reported its second-quarter 2025 earnings, surpassing analysts’ expectations. The company posted an earnings per share (EPS) of -0.01, beating the forecasted -0.03. Additionally, Xeris achieved a revenue of $71.5 million, exceeding projections by 11.85%. These results highlight a strong performance for the quarter. In analyst coverage, H.C. Wainwright has assumed coverage of Xeris Pharmaceuticals with a Buy rating and set a price target of $10.00. The firm noted that Xeris stock has risen significantly, with a 108% increase year to date in 2025. These developments suggest a positive outlook from analysts and strong financial performance from the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.